IKNA Stock Overview
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.
Ikena Oncology, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.07|
|52 Week High||US$17.50|
|52 Week Low||US$2.83|
|1 Month Change||-1.17%|
|3 Month Change||37.03%|
|1 Year Change||-55.49%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-84.16%|
Recent News & Updates
Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|IKNA||US Pharmaceuticals||US Market|
Return vs Industry: IKNA underperformed the US Pharmaceuticals industry which returned -0.9% over the past year.
Return vs Market: IKNA underperformed the US Market which returned -8.9% over the past year.
|IKNA Average Weekly Movement||17.0%|
|Pharmaceuticals Industry Average Movement||12.1%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: IKNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: IKNA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.
Ikena Oncology, Inc. Fundamentals Summary
|IKNA fundamental statistics|
Is IKNA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IKNA income statement (TTM)|
|Cost of Revenue||US$55.54m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.35|
|Net Profit Margin||-176.89%|
How did IKNA perform over the long term?See historical performance and comparison